Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zerlasiran · SLN-360

Oligonucleotide (siRNA) · Gene silencing: LPA mRNA (LPA) · developed by Silence Therapeutics

Phase 2 Most advanced trial (none active)
SLN Developer
2 Registered trials

What is Zerlasiran?

Zerlasiran (SLN360) is a double-stranded small interfering RNA that targets LPA messenger RNA, reducing production of the apolipoprotein(a) component of lipoprotein(a). It is being studied in elevated lipoprotein(a), hyperlipidemias, dyslipidemias, and cardiovascular diseases including atherosclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SLN-360
Drug type
Oligonucleotide (siRNA)
Targets
LPA mRNA (LPA)
Mechanism
Gene silencing: LPA mRNA (LPA)
Therapy area
Cardiovascular, Metabolic
Developer
Silence Therapeutics plc (SLN)
Also in trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FBX7PTD863

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05537571 Phase 2 Cardiovascular Diseases Completed SLN
NCT04606602 Phase 1 Hyperlipidemias Completed MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AtherosclerosisCardiovascular DiseasesDyslipidemiasElevated Lp(a)HyperlipidemiasLipoprotein(a)

Other drugs acting on LPA

More from Silence Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SLN page.

Follow SLN, the company behind Zerlasiran

See SLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.